Recent News

• 02.05.2026 - Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
• 01.26.2026 - Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
• 01.22.2026 - Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
• 01.12.2026 - Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.07.2026 - Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
• 01.05.2026 - Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
• 01.05.2026 - Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Recent Filings

• 02.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.02.2026 - 144 Report of proposed sale of securities
• 01.26.2026 - 8-K Current report
• 01.13.2026 - 8-K Current report
• 01.13.2026 - EX-99.1 EX-99.1
• 01.07.2026 - 8-K Current report
• 01.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.07.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.07.2026 - EX-99.1 EX-99.1
• 01.05.2026 - 424B5 Prospectus [Rule 424(b)(5)]